Eurofins Reinforces Its North American Footprint with the Acquisition of Exova’s Environment Testing Laboratories in Easter...
December 06 2016 - 4:00AM
Business Wire
Regulatory News:
Eurofins Scientific (EUFI.PA) (Paris:ERF), a world leader in
bioanalytical testing, announces that it has acquired Exova’s
environment testing business in Eastern Canada for about CAD 13m.
The acquired business includes 5 laboratories in Quebec and
Ontario, employing about 160 staff, and generated around CAD 19m of
revenues in 2015.
The acquisition reinforces Eurofins’ nascent footprint in
Canada, which started with the acquisition in May 2015 of
Experchem, a laboratory focused on nutraceuticals testing. Exova’s
laboratories, which serve large industrial companies, local
authorities and consultants, shall expand the Group’s client reach
and provide a wider distribution channel in Eastern Canada for
Eurofins’ large range of analytical services. In return, the
laboratories will have access to the entire Eurofins portfolio of
services and infrastructure, and benefit from the Group’s
logistical, clients, suppliers and laboratories network in North
America, which should support their development in their respective
local markets, and increase their share of their clients’ testing
spend.
Comment from Dr. Gilles Martin, Eurofins CEO: “The 5
Exova laboratories in Quebec and Ontario that just joined our Group
represent a good strategic fit for Eurofins as they accelerate the
deployment of our environment testing capabilities in Canada.
Similar to the transaction earlier this year when Eurofins acquired
Exova’s food, water and pharmaceutical testing business in the UK
and Ireland, I believe this is very positive for both companies, as
it enables each of us to focus our resources on our core areas of
testing. By enabling more focused investments and higher economies
of scale, this should also benefit clients and other stakeholders
in the market.”
For more information about Eurofins, please visit
www.eurofins.com
Notes for the editor:Eurofins – a global leader in
bio-analysis
Eurofins believes it is the world leader in food, environment
and pharmaceutical products testing and that it is also one of the
global independent market leaders in certain testing and laboratory
services for agroscience, genomics and discovery pharmacology and
for supporting clinical studies. In addition, Eurofins is one of
the significant emerging players in specialty clinical diagnostic
testing in Europe and the USA.
With 25,000 staff in more than 250 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 validated
analytical methods for evaluating the safety, identity,
composition, authenticity, origin, traceability and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities and healthcare
practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:This press release contains
forward-looking statements and estimates that involve risks and
uncertainties. The forward-looking statements and estimates
contained herein represent the judgement of Eurofins Scientific’
management as of the date of this release. These forward-looking
statements are not guarantees for future performance, and the
forward-looking events discussed in this release may not occur.
Eurofins Scientific disclaims any intent or obligation to update
any of these forward-looking statements and estimates. All
statements and estimates are made based on the information
available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161206005611/en/
Investor RelationsEurofins Scientific GroupPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Sep 2023 to Sep 2024